Stockscreener 앱 받기
9.20
1.43%
0.13
시간 외 거래:
9.21
0.01
+0.11%
전일 마감가:
$9.07
열려 있는:
$9.35
하루 거래량:
24,817
Relative Volume:
0.61
시가총액:
$147.17M
수익:
-
순이익/손실:
$-33.82M
주가수익비율:
-0.3595
EPS:
-25.5891
순현금흐름:
$-66.04M
1주 성능:
-7.82%
1개월 성능:
+9.26%
6개월 성능:
+4.43%
1년 성능:
+96.58%
1일 변동 폭
$9.0612
$9.52
1주일 범위
$8.83
$10.27
52주 변동 폭
$3.70
$10.75
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
ELTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
9.20 | 149.89M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Market reaction to Elicio Therapeutics Inc.’s recent newsFree Daily Momentum Screener With Alerts - Newser
Is Elicio Therapeutics Inc. stock risky to hold nowFlash Gain Trade Picks - mustnews.co.kr
Elicio Therapeutics Inc. Reaches Critical Trendline SupportBuy Signal Based on Chart Analysis Confirmed - metal.it
Using Bollinger Bands to evaluate Elicio Therapeutics Inc.High Yield Watchlist with Filtered Picks - Newser
How hedge fund analytics apply to Elicio Therapeutics Inc. stockFree Sector Based Breakout Stock Forecast - Newser
Elicio (ELTX) Q2 Loss Beats Estimates - AOL.com
What to expect from Elicio Therapeutics Inc. in the next 30 daysEquity Performance Forecast Based on AI Models - Newser
What does recent volatility data suggest for Elicio Therapeutics Inc.Smart Chart Forecasting with AI Algorithms - Newser
What recovery options are there for Elicio Therapeutics Inc.Entry Timing Tracker with Alert Accuracy - Newser
Is Elicio Therapeutics Inc. meeting your algorithmic filter criteriaTechnical Insight Guide for Safer Trades - Newser
Evaluating Elicio Therapeutics Inc. with trendline analysisFree Daily Stock Market Swing Alerts - Newser
Can trapped investors hope for a rebound in Elicio Therapeutics Inc.AI-Powered Stock Trend Movement Analysis - Newser
Predicting Elicio Therapeutics Inc. trend using moving averagesTechnical Trend Forecast for Investors - Newser
Elicio Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Key External Factors That Drive Elicio Therapeutics Inc. Stock Price MovementsDaily Pick Forecast with Entry Zones - Newser
Elicio Therapeutics (ELTX): Clinical Progress Outpaces Financial Losses - AInvest
Elicio Therapeutics Inc. stock outlook for YEARFree AI Powered High Return Stock Calls - Newser
Elicio Therapeutics Extends Cash Runway And Advances Cancer Trial - Finimize
Elicio Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Positive Trial Results: Elicio's Pancreatic Cancer Vaccine Shows Promise, Final Data Coming Q4 2025 - Stock Titan
Analyzing Elicio Therapeutics Inc. with multi timeframe chartsFree Reliable Chart-Based Trade Entries - Newser
What makes Elicio Therapeutics Inc. stock price move sharplyValue Investing Checklist with Entry Signals - Newser
Why Elicio Therapeutics Inc. stock attracts strong analyst attentionFree Capital Efficiency Optimized Stock Alerts - Newser
Is Elicio Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Early Entry Picks Before News Breakout - Newser
How Elicio Therapeutics Inc. stock performs during market volatilitySmart Entry Watchlist with Daily Analysis - Newser
Analyzing recovery setups for Elicio Therapeutics Inc. investorsSmart Forecast Signals from AI Models - Newser
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2 - TipRanks
Elicio Therapeutics Advances Phase 2 AMPLIFY-7P Study - TipRanks
Elicio Therapeutics Announces Positive Recommendation by - GlobeNewswire
Breakthrough: Pancreatic Cancer Vaccine ELI-002 Clears Critical Phase 2 Safety Review, Final Results Due Q4 2025 - Stock Titan
Elicio Therapeutics Inc. recovery potential after sell offPrice Action Based Buy Zone Forecast - Newser
Visual trend scoring systems applied to Elicio Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
Elicio Therapeutics Inc. Recovery Linked to Earnings SurpriseCapital Growth Entry Forecast Insight - beatles.ru
What analysts say about Elicio Therapeutics Inc. stockMarket-beating returns - Jammu Links News
What is the dividend policy of Elicio Therapeutics Inc. stockBuild wealth faster with consistent growth stocks - Jammu Links News
Why is Elicio Therapeutics Inc. stock attracting strong analyst attentionTriple-digit returns - Jammu Links News
How strong is Elicio Therapeutics Inc. company’s balance sheetFree Stock Market Beginners Guide - Jammu Links News
Is Elicio Therapeutics Inc. a good long term investmentGame-changing returns - Jammu Links News
How does Elicio Therapeutics Inc. generate profit in a changing economyBuild wealth with high-performing stocks - Jammu Links News
How volatile is Elicio Therapeutics Inc. stock compared to the marketNavigate market shifts with confidence - Jammu Links News
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):